<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763866</url>
  </required_header>
  <id_info>
    <org_study_id>20110115</org_study_id>
    <secondary_id>2012-001363-70</secondary_id>
    <nct_id>NCT01763866</nct_id>
  </id_info>
  <brief_title>LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2</brief_title>
  <acronym>LAPLACE-2</acronym>
  <official_title>A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the effect of 12 weeks of evolocumab administered
      subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin,
      compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol
      (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to the first randomization, participants entered a screening period to determine
      eligibility. During screening, all participants received subcutaneous placebo corresponding
      to the once monthly dose volume. Participants who completed the screening period and met
      eligibility criteria were randomized to 1 of 5 open-label statin cohorts (atorvastatin 10 mg
      or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg) for a 4 week lipid stabilization
      period based on statin therapy at the time of study entry (no statin use vs non-intensive
      statin use vs intensive statin use).

      After the 4-week lipid-stabilization period, eligible patients taking rosuvastatin or
      simvastatin during the lipid-stabilization phase were then randomized to 1 of 4 treatment
      groups: evolocumab (140 mg, subcutaneous, every 2 weeks) or matching placebo (subcutaneous,
      every 2 weeks), or evolocumab (420 mg, subcutaneous, monthly) or matching placebo
      (subcutaneous, monthly). Patients taking atorvastatin during the lipid-stabilization phase
      were then randomized to 1 of 6 treatment groups: evolocumab (140 mg, subcutaneous, every 2
      weeks) and placebo (oral, daily), evolocumab (420 mg, subcutaneous, monthly) and placebo
      (oral, daily), placebo (subcutaneous, every 2 weeks) and placebo (oral, daily) or ezetimibe
      (10 mg, oral, daily), or placebo (subcutaneous, monthly) and placebo (oral, daily) or
      ezetimibe (10 mg, oral, daily).

      A participant was considered randomized into the study after successfully completing the
      screening period, meeting all inclusion/exclusion criteria, and undergoing both randomization
      procedures.

      Participants randomized to simvastatin who were taking verapamil or diltiazem prior to
      randomization received simvastatin 10 mg once daily (QD) while participants who were taking
      amlodipine, amiodarone or ranolazine prior to randomization received simvastatin 20 mg QD.
      All other participants randomized to simvastatin received simvastatin 40 mg QD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</measure>
    <time_frame>Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>24</number_of_arms>
  <enrollment type="Actual">2067</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>A10 PBO Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A10 PBO QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A10 EZE (Q2W)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A10 EZE (QM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A10 EvoMab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A10 EvoMab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 PBO Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 PBO QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 EZE (Q2W)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 EZE (QM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 EvoMab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A80 EvoMab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R5 PBO Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R5 PBO QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R5 EvoMab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R5 EvoMab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R40 PBO Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R40 PBO QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R40 EvoMab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R40 EvoMab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S40 PBO Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S40 PBO QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S40 EvoMab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S40 EvoMab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>A10 EvoMab Q2W</arm_group_label>
    <arm_group_label>A10 EvoMab QM</arm_group_label>
    <arm_group_label>A80 EvoMab Q2W</arm_group_label>
    <arm_group_label>A80 EvoMab QM</arm_group_label>
    <arm_group_label>R5 EvoMab Q2W</arm_group_label>
    <arm_group_label>R5 EvoMab QM</arm_group_label>
    <arm_group_label>R40 EvoMab Q2W</arm_group_label>
    <arm_group_label>R40 EvoMab QM</arm_group_label>
    <arm_group_label>S40 EvoMab Q2W</arm_group_label>
    <arm_group_label>S40 EvoMab QM</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>A10 EZE (Q2W)</arm_group_label>
    <arm_group_label>A10 EZE (QM)</arm_group_label>
    <arm_group_label>A80 EZE (Q2W)</arm_group_label>
    <arm_group_label>A80 EZE (QM)</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>A10 PBO Q2W</arm_group_label>
    <arm_group_label>A10 PBO QM</arm_group_label>
    <arm_group_label>A10 EZE (Q2W)</arm_group_label>
    <arm_group_label>A10 EZE (QM)</arm_group_label>
    <arm_group_label>A80 PBO Q2W</arm_group_label>
    <arm_group_label>A80 PBO QM</arm_group_label>
    <arm_group_label>A80 EZE (Q2W)</arm_group_label>
    <arm_group_label>A80 EZE (QM)</arm_group_label>
    <arm_group_label>R5 PBO Q2W</arm_group_label>
    <arm_group_label>R5 PBO QM</arm_group_label>
    <arm_group_label>R40 PBO Q2W</arm_group_label>
    <arm_group_label>R40 PBO QM</arm_group_label>
    <arm_group_label>S40 PBO Q2W</arm_group_label>
    <arm_group_label>S40 PBO QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ezetimibe</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>A10 PBO Q2W</arm_group_label>
    <arm_group_label>A10 PBO QM</arm_group_label>
    <arm_group_label>A10 EvoMab Q2W</arm_group_label>
    <arm_group_label>A10 EvoMab QM</arm_group_label>
    <arm_group_label>A80 PBO Q2W</arm_group_label>
    <arm_group_label>A80 PBO QM</arm_group_label>
    <arm_group_label>A80 EvoMab Q2W</arm_group_label>
    <arm_group_label>A80 EvoMab QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>A10 PBO Q2W</arm_group_label>
    <arm_group_label>A10 PBO QM</arm_group_label>
    <arm_group_label>A10 EZE (Q2W)</arm_group_label>
    <arm_group_label>A10 EZE (QM)</arm_group_label>
    <arm_group_label>A10 EvoMab Q2W</arm_group_label>
    <arm_group_label>A10 EvoMab QM</arm_group_label>
    <arm_group_label>A80 PBO Q2W</arm_group_label>
    <arm_group_label>A80 PBO QM</arm_group_label>
    <arm_group_label>A80 EZE (Q2W)</arm_group_label>
    <arm_group_label>A80 EZE (QM)</arm_group_label>
    <arm_group_label>A80 EvoMab Q2W</arm_group_label>
    <arm_group_label>A80 EvoMab QM</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>R5 PBO Q2W</arm_group_label>
    <arm_group_label>R5 PBO QM</arm_group_label>
    <arm_group_label>R5 EvoMab Q2W</arm_group_label>
    <arm_group_label>R5 EvoMab QM</arm_group_label>
    <arm_group_label>R40 PBO Q2W</arm_group_label>
    <arm_group_label>R40 PBO QM</arm_group_label>
    <arm_group_label>R40 EvoMab Q2W</arm_group_label>
    <arm_group_label>R40 EvoMab QM</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>S40 PBO Q2W</arm_group_label>
    <arm_group_label>S40 PBO QM</arm_group_label>
    <arm_group_label>S40 EvoMab Q2W</arm_group_label>
    <arm_group_label>S40 EvoMab QM</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0
             mmol/L)

          -  Subjects already on a non-intensive statin must have fasting LDL-C at screening ≥ 100
             mg/dL (2.6 mmol/L)

          -  Subjects already on a intensive statin must have fasting LDL-C at screening ≥ 80 mg/dL
             (2.1 mmol/L)

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

        Exclusion Criteria:

          -  Statin intolerance

          -  New York Heart association (NYHA) III or IV heart failure

          -  Uncontrolled hypertension

          -  Uncontrolled cardiac arrhythmia

          -  Type 1 diabetes, poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <zip>46320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cadiz</city>
        <state>Ohio</state>
        <zip>43907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2022</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullarton</city>
        <state>South Australia</state>
        <zip>5063</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blankenberge</city>
        <zip>8370</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ChÃªnÃ©e</city>
        <zip>4032</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tremelo</city>
        <zip>3120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilvoorde</city>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Johnâ€™s</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M8V 3X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brossard</city>
        <state>Quebec</state>
        <zip>J4X 1S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lachine</city>
        <state>Quebec</state>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4N 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>603 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kladno</city>
        <zip>272 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Litomerice</city>
        <zip>412 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moravske Budejovice</city>
        <zip>676 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svitavy</city>
        <zip>568 25</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin (Hellersdorf)</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messkirch</city>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berettyoujfalu</city>
        <zip>4100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunaujvaros</city>
        <zip>2400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hodmezovasarhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaszbereny</city>
        <zip>5100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komarom</city>
        <zip>2921</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marcali</city>
        <zip>8700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trieste</city>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>03800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37520</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis PotosÃ-</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampico</city>
        <state>Tamaulipas</state>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <zip>34270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alberton</city>
        <state>Gauteng</state>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyttelton</city>
        <state>Gauteng</state>
        <zip>0140</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuils River</city>
        <state>Western Cape</state>
        <zip>7580</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <state>AndalucÃ-a</state>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>AlmerÃ-a</city>
        <state>AndalucÃ-a</state>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>CataluÃ±a</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozuelo de AlarcÃ³n</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>222 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>222 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ã-rebro</city>
        <zip>701 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geneva 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muensterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN9 1EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G45 9AW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA3 7LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0FT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scunthorpe</city>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whitby</city>
        <zip>YO21 1SD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252. Epub 2014 Jan 30.</citation>
    <PMID>24481874</PMID>
  </reference>
  <reference>
    <citation>Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.</citation>
    <PMID>24825642</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <results_first_submitted>September 1, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2015</results_first_posted>
  <disposition_first_submitted>May 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 20, 2014</disposition_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults aged 18 to 80 years with screening low-density lipoprotein cholesterol (LDL-C) ≥ 150 mg/dL (no statin at screening), ≥ 100 mg/dL (non-intensive statin at screening), or ≥ 80 mg/dL (intensive statin at screening) and fasting triglycerides ≤ 400 mg/dL.
First patient enrolled on 15 January 2013; Last patient enrolled on 10 July 2013.</recruitment_details>
      <pre_assignment_details>2067 patients were first randomized to 1 of the 5 open-label statin cohorts (atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg); 1899 were then randomized to blinded investigational product.
Randomization into the statin dose cohorts was stratified by entry statin therapy and by use of certain concomitant medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A10 PBO Q2W</title>
          <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>A10 PBO QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>A10 EZE (Q2W)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>A10 EZE (QM)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>A10 EvoMab Q2W</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>A10 EvoMab QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>A80 PBO Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>A80 PBO QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P9">
          <title>A80 EZE (Q2W)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P10">
          <title>A80 EZE (QM)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P11">
          <title>A80 EvoMab Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P12">
          <title>A80 EvoMab QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P13">
          <title>R5 PBO Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P14">
          <title>R5 PBO QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="P15">
          <title>R5 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P16">
          <title>R5 EvoMab QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="P17">
          <title>R40 PBO Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P18">
          <title>R40 PBO QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="P19">
          <title>R40 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P20">
          <title>R40 EvoMab QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="P21">
          <title>S40 PBO Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P22">
          <title>S40 PBO QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="P23">
          <title>S40 EvoMab Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="P24">
          <title>S40 EvoMab QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="110"/>
                <participants group_id="P6" count="110"/>
                <participants group_id="P7" count="55"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="56"/>
                <participants group_id="P10" count="54"/>
                <participants group_id="P11" count="110"/>
                <participants group_id="P12" count="110"/>
                <participants group_id="P13" count="58"/>
                <participants group_id="P14" count="57"/>
                <participants group_id="P15" count="114"/>
                <participants group_id="P16" count="115"/>
                <participants group_id="P17" count="56"/>
                <participants group_id="P18" count="56"/>
                <participants group_id="P19" count="111"/>
                <participants group_id="P20" count="112"/>
                <participants group_id="P21" count="56"/>
                <participants group_id="P22" count="55"/>
                <participants group_id="P23" count="112"/>
                <participants group_id="P24" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="110"/>
                <participants group_id="P6" count="110"/>
                <participants group_id="P7" count="55"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="56"/>
                <participants group_id="P10" count="54"/>
                <participants group_id="P11" count="109"/>
                <participants group_id="P12" count="110"/>
                <participants group_id="P13" count="58"/>
                <participants group_id="P14" count="57"/>
                <participants group_id="P15" count="113"/>
                <participants group_id="P16" count="115"/>
                <participants group_id="P17" count="56"/>
                <participants group_id="P18" count="55"/>
                <participants group_id="P19" count="111"/>
                <participants group_id="P20" count="112"/>
                <participants group_id="P21" count="56"/>
                <participants group_id="P22" count="55"/>
                <participants group_id="P23" count="112"/>
                <participants group_id="P24" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="108"/>
                <participants group_id="P6" count="107"/>
                <participants group_id="P7" count="48"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="53"/>
                <participants group_id="P10" count="53"/>
                <participants group_id="P11" count="102"/>
                <participants group_id="P12" count="108"/>
                <participants group_id="P13" count="54"/>
                <participants group_id="P14" count="57"/>
                <participants group_id="P15" count="102"/>
                <participants group_id="P16" count="112"/>
                <participants group_id="P17" count="55"/>
                <participants group_id="P18" count="55"/>
                <participants group_id="P19" count="105"/>
                <participants group_id="P20" count="110"/>
                <participants group_id="P21" count="52"/>
                <participants group_id="P22" count="54"/>
                <participants group_id="P23" count="109"/>
                <participants group_id="P24" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="2"/>
                <participants group_id="P21" count="4"/>
                <participants group_id="P22" count="1"/>
                <participants group_id="P23" count="3"/>
                <participants group_id="P24" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="2"/>
                <participants group_id="P22" count="1"/>
                <participants group_id="P23" count="2"/>
                <participants group_id="P24" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="4"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="2"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="1"/>
                <participants group_id="P24" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A10 PBO Q2W</title>
          <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>A10 PBO QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>A10 EZE (Q2W)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>A10 EZE (QM)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>A10 EvoMab Q2W</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>A10 EvoMab QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>A80 PBO Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>A80 PBO QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>A80 EZE (Q2W)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B10">
          <title>A80 EZE (QM)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B11">
          <title>A80 EvoMab Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B12">
          <title>A80 EvoMab QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B13">
          <title>R5 PBO Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B14">
          <title>R5 PBO QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B15">
          <title>R5 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B16">
          <title>R5 EvoMab QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B17">
          <title>R40 PBO Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B18">
          <title>R40 PBO QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B19">
          <title>R40 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B20">
          <title>R40 EvoMab QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B21">
          <title>S40 PBO Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B22">
          <title>S40 PBO QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B23">
          <title>S40 EvoMab Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="B24">
          <title>S40 EvoMab QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="B25">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="110"/>
            <count group_id="B6" value="110"/>
            <count group_id="B7" value="55"/>
            <count group_id="B8" value="55"/>
            <count group_id="B9" value="56"/>
            <count group_id="B10" value="54"/>
            <count group_id="B11" value="110"/>
            <count group_id="B12" value="110"/>
            <count group_id="B13" value="58"/>
            <count group_id="B14" value="57"/>
            <count group_id="B15" value="114"/>
            <count group_id="B16" value="115"/>
            <count group_id="B17" value="56"/>
            <count group_id="B18" value="56"/>
            <count group_id="B19" value="111"/>
            <count group_id="B20" value="112"/>
            <count group_id="B21" value="56"/>
            <count group_id="B22" value="55"/>
            <count group_id="B23" value="112"/>
            <count group_id="B24" value="115"/>
            <count group_id="B25" value="1899"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="10.5"/>
                    <measurement group_id="B2" value="62.2" spread="10.4"/>
                    <measurement group_id="B3" value="61.0" spread="9.0"/>
                    <measurement group_id="B4" value="60.6" spread="9.2"/>
                    <measurement group_id="B5" value="58.3" spread="8.4"/>
                    <measurement group_id="B6" value="59.6" spread="11.1"/>
                    <measurement group_id="B7" value="57.1" spread="9.9"/>
                    <measurement group_id="B8" value="58.8" spread="11.5"/>
                    <measurement group_id="B9" value="60.5" spread="10.2"/>
                    <measurement group_id="B10" value="61.1" spread="8.9"/>
                    <measurement group_id="B11" value="59.7" spread="10.2"/>
                    <measurement group_id="B12" value="60.1" spread="10.2"/>
                    <measurement group_id="B13" value="61.2" spread="9.1"/>
                    <measurement group_id="B14" value="59.6" spread="9.2"/>
                    <measurement group_id="B15" value="58.9" spread="11.2"/>
                    <measurement group_id="B16" value="59.3" spread="10.5"/>
                    <measurement group_id="B17" value="60.2" spread="8.7"/>
                    <measurement group_id="B18" value="58.3" spread="11.3"/>
                    <measurement group_id="B19" value="59.5" spread="9.2"/>
                    <measurement group_id="B20" value="59.6" spread="9.0"/>
                    <measurement group_id="B21" value="61.9" spread="9.7"/>
                    <measurement group_id="B22" value="61.5" spread="10.3"/>
                    <measurement group_id="B23" value="59.7" spread="9.2"/>
                    <measurement group_id="B24" value="61.5" spread="9.6"/>
                    <measurement group_id="B25" value="59.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="44"/>
                    <measurement group_id="B12" value="48"/>
                    <measurement group_id="B13" value="35"/>
                    <measurement group_id="B14" value="27"/>
                    <measurement group_id="B15" value="52"/>
                    <measurement group_id="B16" value="51"/>
                    <measurement group_id="B17" value="21"/>
                    <measurement group_id="B18" value="27"/>
                    <measurement group_id="B19" value="43"/>
                    <measurement group_id="B20" value="52"/>
                    <measurement group_id="B21" value="32"/>
                    <measurement group_id="B22" value="28"/>
                    <measurement group_id="B23" value="45"/>
                    <measurement group_id="B24" value="59"/>
                    <measurement group_id="B25" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="32"/>
                    <measurement group_id="B10" value="26"/>
                    <measurement group_id="B11" value="66"/>
                    <measurement group_id="B12" value="62"/>
                    <measurement group_id="B13" value="23"/>
                    <measurement group_id="B14" value="30"/>
                    <measurement group_id="B15" value="62"/>
                    <measurement group_id="B16" value="64"/>
                    <measurement group_id="B17" value="35"/>
                    <measurement group_id="B18" value="29"/>
                    <measurement group_id="B19" value="68"/>
                    <measurement group_id="B20" value="60"/>
                    <measurement group_id="B21" value="24"/>
                    <measurement group_id="B22" value="27"/>
                    <measurement group_id="B23" value="67"/>
                    <measurement group_id="B24" value="56"/>
                    <measurement group_id="B25" value="1028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="6"/>
                    <measurement group_id="B20" value="5"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="2"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="5"/>
                    <measurement group_id="B25" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="108"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="52"/>
                    <measurement group_id="B10" value="50"/>
                    <measurement group_id="B11" value="105"/>
                    <measurement group_id="B12" value="103"/>
                    <measurement group_id="B13" value="56"/>
                    <measurement group_id="B14" value="53"/>
                    <measurement group_id="B15" value="108"/>
                    <measurement group_id="B16" value="112"/>
                    <measurement group_id="B17" value="54"/>
                    <measurement group_id="B18" value="53"/>
                    <measurement group_id="B19" value="105"/>
                    <measurement group_id="B20" value="107"/>
                    <measurement group_id="B21" value="55"/>
                    <measurement group_id="B22" value="53"/>
                    <measurement group_id="B23" value="109"/>
                    <measurement group_id="B24" value="110"/>
                    <measurement group_id="B25" value="1812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="7"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="1"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="5"/>
                    <measurement group_id="B25" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="101"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="53"/>
                    <measurement group_id="B10" value="46"/>
                    <measurement group_id="B11" value="105"/>
                    <measurement group_id="B12" value="105"/>
                    <measurement group_id="B13" value="56"/>
                    <measurement group_id="B14" value="56"/>
                    <measurement group_id="B15" value="104"/>
                    <measurement group_id="B16" value="107"/>
                    <measurement group_id="B17" value="55"/>
                    <measurement group_id="B18" value="52"/>
                    <measurement group_id="B19" value="105"/>
                    <measurement group_id="B20" value="109"/>
                    <measurement group_id="B21" value="49"/>
                    <measurement group_id="B22" value="54"/>
                    <measurement group_id="B23" value="106"/>
                    <measurement group_id="B24" value="110"/>
                    <measurement group_id="B25" value="1785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Entry Statin Therapy</title>
          <description>Intensive statin use was defined as daily atorvastatin (40 mg or greater), rosuvastatin (20 mg or greater), simvastatin (80 mg), or any statin plus ezetimibe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Intensive statin use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="34"/>
                    <measurement group_id="B12" value="35"/>
                    <measurement group_id="B13" value="13"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="33"/>
                    <measurement group_id="B16" value="38"/>
                    <measurement group_id="B17" value="13"/>
                    <measurement group_id="B18" value="13"/>
                    <measurement group_id="B19" value="33"/>
                    <measurement group_id="B20" value="37"/>
                    <measurement group_id="B21" value="19"/>
                    <measurement group_id="B22" value="13"/>
                    <measurement group_id="B23" value="31"/>
                    <measurement group_id="B24" value="34"/>
                    <measurement group_id="B25" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-intensive statin use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="22"/>
                    <measurement group_id="B10" value="21"/>
                    <measurement group_id="B11" value="47"/>
                    <measurement group_id="B12" value="46"/>
                    <measurement group_id="B13" value="25"/>
                    <measurement group_id="B14" value="28"/>
                    <measurement group_id="B15" value="49"/>
                    <measurement group_id="B16" value="42"/>
                    <measurement group_id="B17" value="23"/>
                    <measurement group_id="B18" value="22"/>
                    <measurement group_id="B19" value="50"/>
                    <measurement group_id="B20" value="44"/>
                    <measurement group_id="B21" value="21"/>
                    <measurement group_id="B22" value="26"/>
                    <measurement group_id="B23" value="45"/>
                    <measurement group_id="B24" value="48"/>
                    <measurement group_id="B25" value="796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No statin use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="29"/>
                    <measurement group_id="B13" value="20"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="32"/>
                    <measurement group_id="B16" value="35"/>
                    <measurement group_id="B17" value="20"/>
                    <measurement group_id="B18" value="21"/>
                    <measurement group_id="B19" value="28"/>
                    <measurement group_id="B20" value="31"/>
                    <measurement group_id="B21" value="16"/>
                    <measurement group_id="B22" value="16"/>
                    <measurement group_id="B23" value="36"/>
                    <measurement group_id="B24" value="33"/>
                    <measurement group_id="B25" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein Cholesterol (LDL-C) Concentration</title>
          <description>Data are provided for the full analysis set (all participants randomized to investigational product (IP) who received at least 1 dose of IP (subcutaneously or orally). Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.0" spread="46.6"/>
                    <measurement group_id="B2" value="123.7" spread="47.9"/>
                    <measurement group_id="B3" value="126.8" spread="49.6"/>
                    <measurement group_id="B4" value="119.3" spread="28.1"/>
                    <measurement group_id="B5" value="124.2" spread="43.4"/>
                    <measurement group_id="B6" value="126.1" spread="50.4"/>
                    <measurement group_id="B7" value="100.3" spread="36.2"/>
                    <measurement group_id="B8" value="94.7" spread="31.9"/>
                    <measurement group_id="B9" value="98.7" spread="34.0"/>
                    <measurement group_id="B10" value="92.3" spread="19.3"/>
                    <measurement group_id="B11" value="94.2" spread="34.8"/>
                    <measurement group_id="B12" value="93.8" spread="32.3"/>
                    <measurement group_id="B13" value="115.6" spread="39.8"/>
                    <measurement group_id="B14" value="119.9" spread="39.1"/>
                    <measurement group_id="B15" value="118.7" spread="40.9"/>
                    <measurement group_id="B16" value="122.9" spread="42.0"/>
                    <measurement group_id="B17" value="77.4" spread="20.9"/>
                    <measurement group_id="B18" value="102.9" spread="49.3"/>
                    <measurement group_id="B19" value="88.5" spread="31.5"/>
                    <measurement group_id="B20" value="88.5" spread="31.3"/>
                    <measurement group_id="B21" value="110.3" spread="28.0"/>
                    <measurement group_id="B22" value="108.6" spread="30.9"/>
                    <measurement group_id="B23" value="114.9" spread="34.5"/>
                    <measurement group_id="B24" value="123.7" spread="48.5"/>
                    <measurement group_id="B25" value="109.1" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149.1" spread="46.9"/>
                    <measurement group_id="B2" value="147.7" spread="51.4"/>
                    <measurement group_id="B3" value="153.8" spread="53.2"/>
                    <measurement group_id="B4" value="148.3" spread="36.8"/>
                    <measurement group_id="B5" value="152.3" spread="45.6"/>
                    <measurement group_id="B6" value="154.3" spread="53.1"/>
                    <measurement group_id="B7" value="124.2" spread="39.3"/>
                    <measurement group_id="B8" value="116.5" spread="35.7"/>
                    <measurement group_id="B9" value="124.8" spread="35.4"/>
                    <measurement group_id="B10" value="118.4" spread="25.5"/>
                    <measurement group_id="B11" value="120.2" spread="42.3"/>
                    <measurement group_id="B12" value="117.2" spread="36.3"/>
                    <measurement group_id="B13" value="141.1" spread="41.6"/>
                    <measurement group_id="B14" value="148.3" spread="43.3"/>
                    <measurement group_id="B15" value="146.6" spread="43.2"/>
                    <measurement group_id="B16" value="152.0" spread="46.4"/>
                    <measurement group_id="B17" value="103.9" spread="25.7"/>
                    <measurement group_id="B18" value="128.7" spread="53.4"/>
                    <measurement group_id="B19" value="113.5" spread="36.0"/>
                    <measurement group_id="B20" value="114.3" spread="34.7"/>
                    <measurement group_id="B21" value="138.4" spread="29.3"/>
                    <measurement group_id="B22" value="135.7" spread="38.4"/>
                    <measurement group_id="B23" value="146.8" spread="41.8"/>
                    <measurement group_id="B24" value="151.2" spread="51.5"/>
                    <measurement group_id="B25" value="150.3" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.3" spread="26.0"/>
                    <measurement group_id="B2" value="95.3" spread="29.6"/>
                    <measurement group_id="B3" value="101.3" spread="31.2"/>
                    <measurement group_id="B4" value="94.6" spread="20.4"/>
                    <measurement group_id="B5" value="99.7" spread="26.4"/>
                    <measurement group_id="B6" value="97.3" spread="28.9"/>
                    <measurement group_id="B7" value="81.1" spread="22.1"/>
                    <measurement group_id="B8" value="80.1" spread="21.4"/>
                    <measurement group_id="B9" value="85.3" spread="23.1"/>
                    <measurement group_id="B10" value="78.7" spread="16.9"/>
                    <measurement group_id="B11" value="79.9" spread="25.1"/>
                    <measurement group_id="B12" value="77.9" spread="21.5"/>
                    <measurement group_id="B13" value="93.1" spread="27.3"/>
                    <measurement group_id="B14" value="95.9" spread="25.2"/>
                    <measurement group_id="B15" value="95.4" spread="27.0"/>
                    <measurement group_id="B16" value="97.2" spread="26.9"/>
                    <measurement group_id="B17" value="71.0" spread="16.6"/>
                    <measurement group_id="B18" value="84.8" spread="29.7"/>
                    <measurement group_id="B19" value="77.4" spread="22.3"/>
                    <measurement group_id="B20" value="78.7" spread="23.1"/>
                    <measurement group_id="B21" value="91.6" spread="18.4"/>
                    <measurement group_id="B22" value="89.8" spread="20.7"/>
                    <measurement group_id="B23" value="94.2" spread="24.0"/>
                    <measurement group_id="B24" value="96.5" spread="27.5"/>
                    <measurement group_id="B25" value="89.1" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/HDL-C Ratio</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.988" spread="1.154"/>
                    <measurement group_id="B2" value="3.859" spread="1.396"/>
                    <measurement group_id="B3" value="4.112" spread="1.311"/>
                    <measurement group_id="B4" value="4.002" spread="1.100"/>
                    <measurement group_id="B5" value="3.980" spread="1.224"/>
                    <measurement group_id="B6" value="4.100" spread="1.636"/>
                    <measurement group_id="B7" value="3.704" spread="1.260"/>
                    <measurement group_id="B8" value="3.461" spread="1.093"/>
                    <measurement group_id="B9" value="3.748" spread="1.099"/>
                    <measurement group_id="B10" value="3.540" spread="1.100"/>
                    <measurement group_id="B11" value="3.696" spread="1.371"/>
                    <measurement group_id="B12" value="3.462" spread="1.000"/>
                    <measurement group_id="B13" value="4.044" spread="1.685"/>
                    <measurement group_id="B14" value="3.891" spread="1.234"/>
                    <measurement group_id="B15" value="3.915" spread="1.216"/>
                    <measurement group_id="B16" value="4.178" spread="1.932"/>
                    <measurement group_id="B17" value="3.086" spread="0.728"/>
                    <measurement group_id="B18" value="3.547" spread="1.355"/>
                    <measurement group_id="B19" value="3.413" spread="1.355"/>
                    <measurement group_id="B20" value="3.307" spread="1.061"/>
                    <measurement group_id="B21" value="3.733" spread="1.079"/>
                    <measurement group_id="B22" value="3.595" spread="1.345"/>
                    <measurement group_id="B23" value="4.196" spread="1.436"/>
                    <measurement group_id="B24" value="3.924" spread="1.420"/>
                    <measurement group_id="B25" value="3.786" spread="1.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A1 Ratio</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.666" spread="0.216"/>
                    <measurement group_id="B2" value="0.647" spread="0.266"/>
                    <measurement group_id="B3" value="0.692" spread="0.243"/>
                    <measurement group_id="B4" value="0.640" spread="0.169"/>
                    <measurement group_id="B5" value="0.663" spread="0.217"/>
                    <measurement group_id="B6" value="0.659" spread="0.249"/>
                    <measurement group_id="B7" value="0.603" spread="0.221"/>
                    <measurement group_id="B8" value="0.571" spread="0.189"/>
                    <measurement group_id="B9" value="0.640" spread="0.234"/>
                    <measurement group_id="B10" value="0.560" spread="0.157"/>
                    <measurement group_id="B11" value="0.593" spread="0.227"/>
                    <measurement group_id="B12" value="0.562" spread="0.171"/>
                    <measurement group_id="B13" value="0.661" spread="0.273"/>
                    <measurement group_id="B14" value="0.636" spread="0.207"/>
                    <measurement group_id="B15" value="0.640" spread="0.249"/>
                    <measurement group_id="B16" value="0.676" spread="0.341"/>
                    <measurement group_id="B17" value="0.479" spread="0.129"/>
                    <measurement group_id="B18" value="0.562" spread="0.217"/>
                    <measurement group_id="B19" value="0.538" spread="0.227"/>
                    <measurement group_id="B20" value="0.536" spread="0.193"/>
                    <measurement group_id="B21" value="0.611" spread="0.179"/>
                    <measurement group_id="B22" value="0.581" spread="0.174"/>
                    <measurement group_id="B23" value="0.657" spread="0.193"/>
                    <measurement group_id="B24" value="0.639" spread="0.224"/>
                    <measurement group_id="B25" value="0.614" spread="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein(a) Concentration</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="13.0" upper_limit="87.5"/>
                    <measurement group_id="B2" value="41.0" lower_limit="15.0" upper_limit="106.0"/>
                    <measurement group_id="B3" value="37.0" lower_limit="9.5" upper_limit="190.0"/>
                    <measurement group_id="B4" value="33.0" lower_limit="8.0" upper_limit="163.0"/>
                    <measurement group_id="B5" value="27.0" lower_limit="8.0" upper_limit="120.0"/>
                    <measurement group_id="B6" value="49.0" lower_limit="11.0" upper_limit="169.0"/>
                    <measurement group_id="B7" value="53.0" lower_limit="15.0" upper_limit="177.0"/>
                    <measurement group_id="B8" value="50.0" lower_limit="13.0" upper_limit="152.0"/>
                    <measurement group_id="B9" value="25.0" lower_limit="12.0" upper_limit="108.0"/>
                    <measurement group_id="B10" value="61.5" lower_limit="12.0" upper_limit="192.0"/>
                    <measurement group_id="B11" value="32.0" lower_limit="11.5" upper_limit="135.5"/>
                    <measurement group_id="B12" value="24.5" lower_limit="8.0" upper_limit="93.0"/>
                    <measurement group_id="B13" value="34.0" lower_limit="8.0" upper_limit="158.0"/>
                    <measurement group_id="B14" value="35.0" lower_limit="14.0" upper_limit="156.5"/>
                    <measurement group_id="B15" value="38.0" lower_limit="11.0" upper_limit="165.0"/>
                    <measurement group_id="B16" value="32.0" lower_limit="9.0" upper_limit="172.0"/>
                    <measurement group_id="B17" value="28.5" lower_limit="7.0" upper_limit="171.0"/>
                    <measurement group_id="B18" value="33.0" lower_limit="11.0" upper_limit="148.0"/>
                    <measurement group_id="B19" value="41.0" lower_limit="10.0" upper_limit="183.0"/>
                    <measurement group_id="B20" value="49.5" lower_limit="11.0" upper_limit="184.5"/>
                    <measurement group_id="B21" value="36.5" lower_limit="17.5" upper_limit="140.5"/>
                    <measurement group_id="B22" value="28.0" lower_limit="13.0" upper_limit="180.0"/>
                    <measurement group_id="B23" value="32.5" lower_limit="13.0" upper_limit="157.0"/>
                    <measurement group_id="B24" value="37.0" lower_limit="11.0" upper_limit="141.0"/>
                    <measurement group_id="B25" value="34.0" lower_limit="11.0" upper_limit="161.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride Concentration</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112.0" lower_limit="83.0" upper_limit="176.0"/>
                    <measurement group_id="B2" value="108.0" lower_limit="83.0" upper_limit="145.0"/>
                    <measurement group_id="B3" value="129.5" lower_limit="94.0" upper_limit="151.5"/>
                    <measurement group_id="B4" value="119.0" lower_limit="87.0" upper_limit="168.0"/>
                    <measurement group_id="B5" value="135.0" lower_limit="99.0" upper_limit="189.0"/>
                    <measurement group_id="B6" value="119.0" lower_limit="84.0" upper_limit="161.0"/>
                    <measurement group_id="B7" value="104.0" lower_limit="82.0" upper_limit="142.0"/>
                    <measurement group_id="B8" value="104.0" lower_limit="76.0" upper_limit="124.0"/>
                    <measurement group_id="B9" value="133.0" lower_limit="89.0" upper_limit="155.0"/>
                    <measurement group_id="B10" value="109.0" lower_limit="80.0" upper_limit="171.0"/>
                    <measurement group_id="B11" value="104.0" lower_limit="81.0" upper_limit="163.0"/>
                    <measurement group_id="B12" value="106.5" lower_limit="79.0" upper_limit="137.0"/>
                    <measurement group_id="B13" value="112.5" lower_limit="89.0" upper_limit="148.0"/>
                    <measurement group_id="B14" value="134.0" lower_limit="86.0" upper_limit="184.0"/>
                    <measurement group_id="B15" value="116.0" lower_limit="90.0" upper_limit="168.0"/>
                    <measurement group_id="B16" value="121.0" lower_limit="93.0" upper_limit="161.0"/>
                    <measurement group_id="B17" value="128.0" lower_limit="91.5" upper_limit="162.0"/>
                    <measurement group_id="B18" value="116.0" lower_limit="78.0" upper_limit="160.0"/>
                    <measurement group_id="B19" value="102.0" lower_limit="79.0" upper_limit="151.0"/>
                    <measurement group_id="B20" value="119.5" lower_limit="87.0" upper_limit="149.5"/>
                    <measurement group_id="B21" value="124.0" lower_limit="90.0" upper_limit="173.0"/>
                    <measurement group_id="B22" value="106.0" lower_limit="87.0" upper_limit="139.0"/>
                    <measurement group_id="B23" value="129.0" lower_limit="91.5" upper_limit="195.0"/>
                    <measurement group_id="B24" value="110.0" lower_limit="84.0" upper_limit="161.0"/>
                    <measurement group_id="B25" value="116.0" lower_limit="86.0" upper_limit="158.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low Density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <description>Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" lower_limit="17.0" upper_limit="35.0"/>
                    <measurement group_id="B2" value="22.0" lower_limit="17.0" upper_limit="29.0"/>
                    <measurement group_id="B3" value="25.5" lower_limit="19.0" upper_limit="30.0"/>
                    <measurement group_id="B4" value="24.0" lower_limit="17.0" upper_limit="33.0"/>
                    <measurement group_id="B5" value="27.0" lower_limit="20.0" upper_limit="38.0"/>
                    <measurement group_id="B6" value="24.0" lower_limit="17.0" upper_limit="32.0"/>
                    <measurement group_id="B7" value="21.0" lower_limit="16.0" upper_limit="28.0"/>
                    <measurement group_id="B8" value="21.0" lower_limit="15.0" upper_limit="25.0"/>
                    <measurement group_id="B9" value="26.5" lower_limit="18.0" upper_limit="31.0"/>
                    <measurement group_id="B10" value="22.0" lower_limit="16.0" upper_limit="34.0"/>
                    <measurement group_id="B11" value="21.0" lower_limit="16.0" upper_limit="33.0"/>
                    <measurement group_id="B12" value="21.0" lower_limit="16.0" upper_limit="27.0"/>
                    <measurement group_id="B13" value="22.5" lower_limit="18.0" upper_limit="30.0"/>
                    <measurement group_id="B14" value="27.0" lower_limit="17.0" upper_limit="37.0"/>
                    <measurement group_id="B15" value="23.0" lower_limit="18.0" upper_limit="34.0"/>
                    <measurement group_id="B16" value="24.0" lower_limit="19.0" upper_limit="32.0"/>
                    <measurement group_id="B17" value="26.0" lower_limit="18.5" upper_limit="32.5"/>
                    <measurement group_id="B18" value="23.0" lower_limit="16.0" upper_limit="32.0"/>
                    <measurement group_id="B19" value="20.0" lower_limit="16.0" upper_limit="30.0"/>
                    <measurement group_id="B20" value="24.0" lower_limit="17.0" upper_limit="30.0"/>
                    <measurement group_id="B21" value="25.0" lower_limit="18.0" upper_limit="34.5"/>
                    <measurement group_id="B22" value="21.0" lower_limit="17.0" upper_limit="26.0"/>
                    <measurement group_id="B23" value="26.0" lower_limit="18.5" upper_limit="39.0"/>
                    <measurement group_id="B24" value="22.0" lower_limit="17.0" upper_limit="32.0"/>
                    <measurement group_id="B25" value="23.0" lower_limit="17.0" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C Concentration</title>
          <description>Data are provided for the full anlaysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="16.6"/>
                    <measurement group_id="B2" value="57.9" spread="18.4"/>
                    <measurement group_id="B3" value="54.1" spread="17.2"/>
                    <measurement group_id="B4" value="52.7" spread="13.7"/>
                    <measurement group_id="B5" value="56.0" spread="17.9"/>
                    <measurement group_id="B6" value="56.1" spread="17.8"/>
                    <measurement group_id="B7" value="50.6" spread="15.6"/>
                    <measurement group_id="B8" value="50.9" spread="13.0"/>
                    <measurement group_id="B9" value="48.7" spread="12.6"/>
                    <measurement group_id="B10" value="51.6" spread="15.1"/>
                    <measurement group_id="B11" value="48.5" spread="12.9"/>
                    <measurement group_id="B12" value="50.8" spread="13.5"/>
                    <measurement group_id="B13" value="52.1" spread="14.9"/>
                    <measurement group_id="B14" value="55.5" spread="16.0"/>
                    <measurement group_id="B15" value="54.5" spread="15.0"/>
                    <measurement group_id="B16" value="54.0" spread="16.0"/>
                    <measurement group_id="B17" value="52.8" spread="12.9"/>
                    <measurement group_id="B18" value="56.0" spread="18.7"/>
                    <measurement group_id="B19" value="53.2" spread="16.4"/>
                    <measurement group_id="B20" value="53.8" spread="14.6"/>
                    <measurement group_id="B21" value="55.0" spread="14.2"/>
                    <measurement group_id="B22" value="59.9" spread="21.8"/>
                    <measurement group_id="B23" value="49.7" spread="12.6"/>
                    <measurement group_id="B24" value="57.3" spread="17.4"/>
                    <measurement group_id="B25" value="53.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="2.53"/>
                    <measurement group_id="O2" value="0.97" spread="2.82"/>
                    <measurement group_id="O3" value="-21.96" spread="2.63"/>
                    <measurement group_id="O4" value="-17.08" spread="2.78"/>
                    <measurement group_id="O5" value="-61.56" spread="1.81"/>
                    <measurement group_id="O6" value="-58.19" spread="1.99"/>
                    <measurement group_id="O7" value="14.49" spread="4.42"/>
                    <measurement group_id="O8" value="11.83" spread="3.85"/>
                    <measurement group_id="O9" value="-14.60" spread="4.29"/>
                    <measurement group_id="O10" value="-19.80" spread="3.85"/>
                    <measurement group_id="O11" value="-61.80" spread="3.04"/>
                    <measurement group_id="O12" value="-58.68" spread="2.74"/>
                    <measurement group_id="O13" value="8.12" spread="2.68"/>
                    <measurement group_id="O14" value="5.10" spread="2.62"/>
                    <measurement group_id="O15" value="-60.09" spread="1.94"/>
                    <measurement group_id="O16" value="-59.40" spread="1.87"/>
                    <measurement group_id="O17" value="9.42" spread="3.60"/>
                    <measurement group_id="O18" value="2.59" spread="4.30"/>
                    <measurement group_id="O19" value="-58.89" spread="2.58"/>
                    <measurement group_id="O20" value="-52.40" spread="2.98"/>
                    <measurement group_id="O21" value="4.70" spread="3.61"/>
                    <measurement group_id="O22" value="3.40" spread="4.94"/>
                    <measurement group_id="O23" value="-65.86" spread="3.05"/>
                    <measurement group_id="O24" value="-57.02" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-71.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.55</ci_lower_limit>
            <ci_upper_limit>-65.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.94</ci_lower_limit>
            <ci_upper_limit>-52.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.81</ci_lower_limit>
            <ci_upper_limit>-33.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.83</ci_lower_limit>
            <ci_upper_limit>-34.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-76.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.87</ci_lower_limit>
            <ci_upper_limit>-65.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-70.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.81</ci_lower_limit>
            <ci_upper_limit>-61.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.54</ci_lower_limit>
            <ci_upper_limit>-36.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.21</ci_lower_limit>
            <ci_upper_limit>-29.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.72</ci_lower_limit>
            <ci_upper_limit>-61.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.84</ci_lower_limit>
            <ci_upper_limit>-58.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.04</ci_lower_limit>
            <ci_upper_limit>-59.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.31</ci_lower_limit>
            <ci_upper_limit>-44.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-70.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.72</ci_lower_limit>
            <ci_upper_limit>-64.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.11</ci_lower_limit>
            <ci_upper_limit>-51.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.54" spread="2.24"/>
                    <measurement group_id="O2" value="0.35" spread="2.60"/>
                    <measurement group_id="O3" value="-23.88" spread="2.34"/>
                    <measurement group_id="O4" value="-18.98" spread="2.57"/>
                    <measurement group_id="O5" value="-61.41" spread="1.61"/>
                    <measurement group_id="O6" value="-62.47" spread="1.83"/>
                    <measurement group_id="O7" value="13.12" spread="3.99"/>
                    <measurement group_id="O8" value="9.76" spread="3.39"/>
                    <measurement group_id="O9" value="-16.85" spread="3.88"/>
                    <measurement group_id="O10" value="-21.25" spread="3.42"/>
                    <measurement group_id="O11" value="-61.80" spread="2.77"/>
                    <measurement group_id="O12" value="-65.05" spread="2.42"/>
                    <measurement group_id="O13" value="7.55" spread="2.39"/>
                    <measurement group_id="O14" value="2.79" spread="2.50"/>
                    <measurement group_id="O15" value="-59.33" spread="1.74"/>
                    <measurement group_id="O16" value="-63.79" spread="1.76"/>
                    <measurement group_id="O17" value="6.57" spread="3.11"/>
                    <measurement group_id="O18" value="-0.02" spread="3.51"/>
                    <measurement group_id="O19" value="-59.08" spread="2.23"/>
                    <measurement group_id="O20" value="-62.94" spread="2.44"/>
                    <measurement group_id="O21" value="3.26" spread="3.40"/>
                    <measurement group_id="O22" value="6.00" spread="4.80"/>
                    <measurement group_id="O23" value="-66.17" spread="2.93"/>
                    <measurement group_id="O24" value="-62.45" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.38</ci_lower_limit>
            <ci_upper_limit>-64.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.06</ci_lower_limit>
            <ci_upper_limit>-56.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.03</ci_lower_limit>
            <ci_upper_limit>-32.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.70</ci_lower_limit>
            <ci_upper_limit>-37.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-74.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.49</ci_lower_limit>
            <ci_upper_limit>-65.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-74.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.00</ci_lower_limit>
            <ci_upper_limit>-66.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.32</ci_lower_limit>
            <ci_upper_limit>-35.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.06</ci_lower_limit>
            <ci_upper_limit>-35.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.67</ci_lower_limit>
            <ci_upper_limit>-61.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.60</ci_lower_limit>
            <ci_upper_limit>-60.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.19</ci_lower_limit>
            <ci_upper_limit>-58.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.37</ci_lower_limit>
            <ci_upper_limit>-54.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.86</ci_lower_limit>
            <ci_upper_limit>-64.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.68</ci_lower_limit>
            <ci_upper_limit>-60.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="3.7"/>
                    <measurement group_id="O2" value="-0.4" spread="4.4"/>
                    <measurement group_id="O3" value="-32.4" spread="3.8"/>
                    <measurement group_id="O4" value="-25.1" spread="4.3"/>
                    <measurement group_id="O5" value="-76.8" spread="2.7"/>
                    <measurement group_id="O6" value="-80.1" spread="3.1"/>
                    <measurement group_id="O7" value="11.0" spread="5.0"/>
                    <measurement group_id="O8" value="5.5" spread="3.7"/>
                    <measurement group_id="O9" value="-13.0" spread="4.9"/>
                    <measurement group_id="O10" value="-21.3" spread="3.7"/>
                    <measurement group_id="O11" value="-58.8" spread="3.5"/>
                    <measurement group_id="O12" value="-60.1" spread="2.6"/>
                    <measurement group_id="O13" value="6.5" spread="3.5"/>
                    <measurement group_id="O14" value="0.1" spread="4.2"/>
                    <measurement group_id="O15" value="-68.9" spread="2.5"/>
                    <measurement group_id="O16" value="-77.8" spread="3.0"/>
                    <measurement group_id="O17" value="3.4" spread="3.0"/>
                    <measurement group_id="O18" value="-4.8" spread="4.2"/>
                    <measurement group_id="O19" value="-52.3" spread="2.2"/>
                    <measurement group_id="O20" value="-55.3" spread="2.9"/>
                    <measurement group_id="O21" value="-5.7" spread="5.2"/>
                    <measurement group_id="O22" value="1.7" spread="6.5"/>
                    <measurement group_id="O23" value="-83.8" spread="4.5"/>
                    <measurement group_id="O24" value="-78.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-83.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-92.6</ci_lower_limit>
            <ci_upper_limit>-74.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-79.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.2</ci_lower_limit>
            <ci_upper_limit>-69.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.4</ci_lower_limit>
            <ci_upper_limit>-35.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.4</ci_lower_limit>
            <ci_upper_limit>-44.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.9</ci_lower_limit>
            <ci_upper_limit>-57.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.5</ci_lower_limit>
            <ci_upper_limit>-56.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.7</ci_lower_limit>
            <ci_upper_limit>-33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.8</ci_lower_limit>
            <ci_upper_limit>-29.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-75.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.9</ci_lower_limit>
            <ci_upper_limit>-67.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-77.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-88.0</ci_lower_limit>
            <ci_upper_limit>-67.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.1</ci_lower_limit>
            <ci_upper_limit>-48.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.6</ci_lower_limit>
            <ci_upper_limit>-40.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-78.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.2</ci_lower_limit>
            <ci_upper_limit>-70.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-80.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-91.7</ci_lower_limit>
            <ci_upper_limit>-68.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.0"/>
                    <measurement group_id="O2" value="0.8" spread="4.5"/>
                    <measurement group_id="O3" value="-30.1" spread="4.1"/>
                    <measurement group_id="O4" value="-23.3" spread="4.5"/>
                    <measurement group_id="O5" value="-77.0" spread="2.9"/>
                    <measurement group_id="O6" value="-75.1" spread="3.2"/>
                    <measurement group_id="O7" value="12.7" spread="5.3"/>
                    <measurement group_id="O8" value="7.0" spread="4.1"/>
                    <measurement group_id="O9" value="-9.9" spread="5.2"/>
                    <measurement group_id="O10" value="-19.5" spread="4.1"/>
                    <measurement group_id="O11" value="-59.0" spread="3.7"/>
                    <measurement group_id="O12" value="-54.8" spread="2.9"/>
                    <measurement group_id="O13" value="7.8" spread="3.8"/>
                    <measurement group_id="O14" value="2.4" spread="4.4"/>
                    <measurement group_id="O15" value="-69.2" spread="2.7"/>
                    <measurement group_id="O16" value="-73.3" spread="3.1"/>
                    <measurement group_id="O17" value="5.1" spread="3.2"/>
                    <measurement group_id="O18" value="-2.0" spread="4.7"/>
                    <measurement group_id="O19" value="-52.1" spread="2.3"/>
                    <measurement group_id="O20" value="-46.7" spread="3.3"/>
                    <measurement group_id="O21" value="-4.5" spread="5.3"/>
                    <measurement group_id="O22" value="-0.6" spread="6.6"/>
                    <measurement group_id="O23" value="-83.5" spread="4.6"/>
                    <measurement group_id="O24" value="-72.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-85.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-95.2</ci_lower_limit>
            <ci_upper_limit>-75.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-75.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.8</ci_lower_limit>
            <ci_upper_limit>-64.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.6</ci_lower_limit>
            <ci_upper_limit>-37.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-51.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.6</ci_lower_limit>
            <ci_upper_limit>-40.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-71.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.4</ci_lower_limit>
            <ci_upper_limit>-59.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.6</ci_lower_limit>
            <ci_upper_limit>-52.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.5</ci_lower_limit>
            <ci_upper_limit>-36.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.2</ci_lower_limit>
            <ci_upper_limit>-25.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-77.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.2</ci_lower_limit>
            <ci_upper_limit>-67.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-75.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.3</ci_lower_limit>
            <ci_upper_limit>-65.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.1</ci_lower_limit>
            <ci_upper_limit>-49.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.9</ci_lower_limit>
            <ci_upper_limit>-33.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-79.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.5</ci_lower_limit>
            <ci_upper_limit>-70.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-71.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.8</ci_lower_limit>
            <ci_upper_limit>-60.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="2.07"/>
                    <measurement group_id="O2" value="1.28" spread="2.44"/>
                    <measurement group_id="O3" value="-20.71" spread="2.15"/>
                    <measurement group_id="O4" value="-16.56" spread="2.41"/>
                    <measurement group_id="O5" value="-53.48" spread="1.48"/>
                    <measurement group_id="O6" value="-56.09" spread="1.71"/>
                    <measurement group_id="O7" value="10.74" spread="3.59"/>
                    <measurement group_id="O8" value="8.45" spread="3.13"/>
                    <measurement group_id="O9" value="-16.19" spread="3.49"/>
                    <measurement group_id="O10" value="-18.79" spread="3.16"/>
                    <measurement group_id="O11" value="-54.44" spread="2.49"/>
                    <measurement group_id="O12" value="-56.31" spread="2.23"/>
                    <measurement group_id="O13" value="7.02" spread="2.11"/>
                    <measurement group_id="O14" value="3.73" spread="2.32"/>
                    <measurement group_id="O15" value="-52.59" spread="1.54"/>
                    <measurement group_id="O16" value="-55.47" spread="1.64"/>
                    <measurement group_id="O17" value="6.19" spread="2.61"/>
                    <measurement group_id="O18" value="1.58" spread="2.90"/>
                    <measurement group_id="O19" value="-52.08" spread="1.88"/>
                    <measurement group_id="O20" value="-55.72" spread="2.01"/>
                    <measurement group_id="O21" value="0.74" spread="3.23"/>
                    <measurement group_id="O22" value="6.81" spread="4.35"/>
                    <measurement group_id="O23" value="-59.33" spread="2.79"/>
                    <measurement group_id="O24" value="-56.01" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.29</ci_lower_limit>
            <ci_upper_limit>-55.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.23</ci_lower_limit>
            <ci_upper_limit>-51.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.84</ci_lower_limit>
            <ci_upper_limit>-27.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.34</ci_lower_limit>
            <ci_upper_limit>-33.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.78</ci_lower_limit>
            <ci_upper_limit>-56.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.32</ci_lower_limit>
            <ci_upper_limit>-57.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.68</ci_lower_limit>
            <ci_upper_limit>-29.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.15</ci_lower_limit>
            <ci_upper_limit>-29.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.73</ci_lower_limit>
            <ci_upper_limit>-54.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.80</ci_lower_limit>
            <ci_upper_limit>-53.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.60</ci_lower_limit>
            <ci_upper_limit>-51.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.29</ci_lower_limit>
            <ci_upper_limit>-50.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.18</ci_lower_limit>
            <ci_upper_limit>-54.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.22</ci_lower_limit>
            <ci_upper_limit>-55.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="2.32"/>
                    <measurement group_id="O2" value="2.43" spread="2.69"/>
                    <measurement group_id="O3" value="-18.27" spread="2.40"/>
                    <measurement group_id="O4" value="-14.78" spread="2.65"/>
                    <measurement group_id="O5" value="-53.39" spread="1.66"/>
                    <measurement group_id="O6" value="-52.20" spread="1.90"/>
                    <measurement group_id="O7" value="11.79" spread="3.87"/>
                    <measurement group_id="O8" value="9.95" spread="3.51"/>
                    <measurement group_id="O9" value="-14.34" spread="3.75"/>
                    <measurement group_id="O10" value="-17.26" spread="3.52"/>
                    <measurement group_id="O11" value="-54.84" spread="2.66"/>
                    <measurement group_id="O12" value="-50.05" spread="2.50"/>
                    <measurement group_id="O13" value="7.92" spread="2.40"/>
                    <measurement group_id="O14" value="5.85" spread="2.42"/>
                    <measurement group_id="O15" value="-52.04" spread="1.74"/>
                    <measurement group_id="O16" value="-51.57" spread="1.72"/>
                    <measurement group_id="O17" value="8.61" spread="3.04"/>
                    <measurement group_id="O18" value="3.35" spread="3.53"/>
                    <measurement group_id="O19" value="-50.97" spread="2.18"/>
                    <measurement group_id="O20" value="-46.42" spread="2.45"/>
                    <measurement group_id="O21" value="1.89" spread="3.38"/>
                    <measurement group_id="O22" value="5.66" spread="4.53"/>
                    <measurement group_id="O23" value="-59.02" spread="2.87"/>
                    <measurement group_id="O24" value="-50.96" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.25</ci_lower_limit>
            <ci_upper_limit>-56.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.40</ci_lower_limit>
            <ci_upper_limit>-48.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.79</ci_lower_limit>
            <ci_upper_limit>-29.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.15</ci_lower_limit>
            <ci_upper_limit>-31.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.88</ci_lower_limit>
            <ci_upper_limit>-57.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.49</ci_lower_limit>
            <ci_upper_limit>-51.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.55</ci_lower_limit>
            <ci_upper_limit>-31.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.30</ci_lower_limit>
            <ci_upper_limit>-24.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.78</ci_lower_limit>
            <ci_upper_limit>-54.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.27</ci_lower_limit>
            <ci_upper_limit>-51.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.95</ci_lower_limit>
            <ci_upper_limit>-52.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.26</ci_lower_limit>
            <ci_upper_limit>-41.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.57</ci_lower_limit>
            <ci_upper_limit>-55.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.63</ci_lower_limit>
            <ci_upper_limit>-48.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="1.89"/>
                    <measurement group_id="O2" value="0.81" spread="2.19"/>
                    <measurement group_id="O3" value="-17.29" spread="2.00"/>
                    <measurement group_id="O4" value="-11.43" spread="2.20"/>
                    <measurement group_id="O5" value="-50.95" spread="1.38"/>
                    <measurement group_id="O6" value="-51.44" spread="1.52"/>
                    <measurement group_id="O7" value="10.20" spread="3.02"/>
                    <measurement group_id="O8" value="5.48" spread="2.83"/>
                    <measurement group_id="O9" value="-14.22" spread="2.98"/>
                    <measurement group_id="O10" value="-13.62" spread="2.87"/>
                    <measurement group_id="O11" value="-49.14" spread="2.13"/>
                    <measurement group_id="O12" value="-53.26" spread="2.02"/>
                    <measurement group_id="O13" value="5.07" spread="1.97"/>
                    <measurement group_id="O14" value="2.54" spread="1.89"/>
                    <measurement group_id="O15" value="-49.79" spread="1.46"/>
                    <measurement group_id="O16" value="-53.59" spread="1.32"/>
                    <measurement group_id="O17" value="3.71" spread="2.46"/>
                    <measurement group_id="O18" value="1.98" spread="2.57"/>
                    <measurement group_id="O19" value="-47.07" spread="1.76"/>
                    <measurement group_id="O20" value="-52.95" spread="1.76"/>
                    <measurement group_id="O21" value="-0.31" spread="3.02"/>
                    <measurement group_id="O22" value="2.49" spread="4.67"/>
                    <measurement group_id="O23" value="-55.65" spread="2.63"/>
                    <measurement group_id="O24" value="-54.37" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.10</ci_lower_limit>
            <ci_upper_limit>-53.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.49</ci_lower_limit>
            <ci_upper_limit>-47.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.33</ci_lower_limit>
            <ci_upper_limit>-28.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.27</ci_lower_limit>
            <ci_upper_limit>-34.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.61</ci_lower_limit>
            <ci_upper_limit>-52.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.56</ci_lower_limit>
            <ci_upper_limit>-51.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.09</ci_lower_limit>
            <ci_upper_limit>-27.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.57</ci_lower_limit>
            <ci_upper_limit>-32.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.66</ci_lower_limit>
            <ci_upper_limit>-50.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.66</ci_lower_limit>
            <ci_upper_limit>-51.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.72</ci_lower_limit>
            <ci_upper_limit>-44.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.11</ci_lower_limit>
            <ci_upper_limit>-48.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.94</ci_lower_limit>
            <ci_upper_limit>-50.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.27</ci_lower_limit>
            <ci_upper_limit>-50.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="2.16"/>
                    <measurement group_id="O2" value="0.21" spread="2.43"/>
                    <measurement group_id="O3" value="-15.98" spread="2.26"/>
                    <measurement group_id="O4" value="-10.95" spread="2.44"/>
                    <measurement group_id="O5" value="-50.90" spread="1.56"/>
                    <measurement group_id="O6" value="-47.15" spread="1.70"/>
                    <measurement group_id="O7" value="11.64" spread="3.28"/>
                    <measurement group_id="O8" value="6.54" spread="3.22"/>
                    <measurement group_id="O9" value="-12.31" spread="3.20"/>
                    <measurement group_id="O10" value="-12.16" spread="3.24"/>
                    <measurement group_id="O11" value="-49.77" spread="2.28"/>
                    <measurement group_id="O12" value="-46.47" spread="2.31"/>
                    <measurement group_id="O13" value="6.35" spread="2.10"/>
                    <measurement group_id="O14" value="4.63" spread="2.11"/>
                    <measurement group_id="O15" value="-50.15" spread="1.54"/>
                    <measurement group_id="O16" value="-48.58" spread="1.49"/>
                    <measurement group_id="O17" value="4.91" spread="2.71"/>
                    <measurement group_id="O18" value="3.24" spread="3.13"/>
                    <measurement group_id="O19" value="-45.61" spread="1.93"/>
                    <measurement group_id="O20" value="-43.71" spread="2.13"/>
                    <measurement group_id="O21" value="0.35" spread="3.17"/>
                    <measurement group_id="O22" value="3.57" spread="4.74"/>
                    <measurement group_id="O23" value="-55.95" spread="2.72"/>
                    <measurement group_id="O24" value="-49.16" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.03</ci_lower_limit>
            <ci_upper_limit>-53.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.20</ci_lower_limit>
            <ci_upper_limit>-41.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.23</ci_lower_limit>
            <ci_upper_limit>-29.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.06</ci_lower_limit>
            <ci_upper_limit>-30.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.27</ci_lower_limit>
            <ci_upper_limit>-53.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.77</ci_lower_limit>
            <ci_upper_limit>-45.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.17</ci_lower_limit>
            <ci_upper_limit>-29.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.15</ci_lower_limit>
            <ci_upper_limit>-26.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.60</ci_lower_limit>
            <ci_upper_limit>-51.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.29</ci_lower_limit>
            <ci_upper_limit>-48.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.06</ci_lower_limit>
            <ci_upper_limit>-43.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.43</ci_lower_limit>
            <ci_upper_limit>-39.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.47</ci_lower_limit>
            <ci_upper_limit>-51.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.40</ci_lower_limit>
            <ci_upper_limit>-46.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" spread="1.76"/>
                    <measurement group_id="O2" value="2.24" spread="2.11"/>
                    <measurement group_id="O3" value="-14.39" spread="1.83"/>
                    <measurement group_id="O4" value="-10.86" spread="2.08"/>
                    <measurement group_id="O5" value="-40.44" spread="1.26"/>
                    <measurement group_id="O6" value="-42.45" spread="1.48"/>
                    <measurement group_id="O7" value="4.26" spread="2.59"/>
                    <measurement group_id="O8" value="6.42" spread="2.34"/>
                    <measurement group_id="O9" value="-11.92" spread="2.52"/>
                    <measurement group_id="O10" value="-12.25" spread="2.35"/>
                    <measurement group_id="O11" value="-40.22" spread="1.80"/>
                    <measurement group_id="O12" value="-40.43" spread="1.66"/>
                    <measurement group_id="O13" value="5.41" spread="1.96"/>
                    <measurement group_id="O14" value="5.02" spread="2.25"/>
                    <measurement group_id="O15" value="-39.33" spread="1.43"/>
                    <measurement group_id="O16" value="-42.00" spread="1.59"/>
                    <measurement group_id="O17" value="4.55" spread="1.98"/>
                    <measurement group_id="O18" value="1.71" spread="2.36"/>
                    <measurement group_id="O19" value="-36.04" spread="1.42"/>
                    <measurement group_id="O20" value="-38.62" spread="1.64"/>
                    <measurement group_id="O21" value="-0.14" spread="2.79"/>
                    <measurement group_id="O22" value="5.45" spread="3.50"/>
                    <measurement group_id="O23" value="-47.20" spread="2.37"/>
                    <measurement group_id="O24" value="-43.17" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.66</ci_lower_limit>
            <ci_upper_limit>-42.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.75</ci_lower_limit>
            <ci_upper_limit>-39.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-26.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.36</ci_lower_limit>
            <ci_upper_limit>-21.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.61</ci_lower_limit>
            <ci_upper_limit>-26.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.69</ci_lower_limit>
            <ci_upper_limit>-38.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.48</ci_lower_limit>
            <ci_upper_limit>-41.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.39</ci_lower_limit>
            <ci_upper_limit>-22.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.86</ci_lower_limit>
            <ci_upper_limit>-22.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.50</ci_lower_limit>
            <ci_upper_limit>-39.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.46</ci_lower_limit>
            <ci_upper_limit>-41.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.38</ci_lower_limit>
            <ci_upper_limit>-35.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.00</ci_lower_limit>
            <ci_upper_limit>-34.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.76</ci_lower_limit>
            <ci_upper_limit>-42.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.27</ci_lower_limit>
            <ci_upper_limit>-42.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="2.02"/>
                    <measurement group_id="O2" value="2.80" spread="2.31"/>
                    <measurement group_id="O3" value="-12.14" spread="2.10"/>
                    <measurement group_id="O4" value="-9.85" spread="2.28"/>
                    <measurement group_id="O5" value="-40.74" spread="1.45"/>
                    <measurement group_id="O6" value="-40.07" spread="1.63"/>
                    <measurement group_id="O7" value="4.31" spread="2.75"/>
                    <measurement group_id="O8" value="6.18" spread="2.73"/>
                    <measurement group_id="O9" value="-10.53" spread="2.66"/>
                    <measurement group_id="O10" value="-11.06" spread="2.73"/>
                    <measurement group_id="O11" value="-40.79" spread="1.89"/>
                    <measurement group_id="O12" value="-36.25" spread="1.94"/>
                    <measurement group_id="O13" value="4.68" spread="2.28"/>
                    <measurement group_id="O14" value="6.07" spread="2.36"/>
                    <measurement group_id="O15" value="-38.57" spread="1.64"/>
                    <measurement group_id="O16" value="-39.26" spread="1.68"/>
                    <measurement group_id="O17" value="5.96" spread="2.28"/>
                    <measurement group_id="O18" value="2.69" spread="2.80"/>
                    <measurement group_id="O19" value="-35.17" spread="1.63"/>
                    <measurement group_id="O20" value="-32.30" spread="1.94"/>
                    <measurement group_id="O21" value="-0.20" spread="2.81"/>
                    <measurement group_id="O22" value="5.13" spread="3.62"/>
                    <measurement group_id="O23" value="-47.24" spread="2.38"/>
                    <measurement group_id="O24" value="-39.47" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.73</ci_lower_limit>
            <ci_upper_limit>-41.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.43</ci_lower_limit>
            <ci_upper_limit>-37.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.56</ci_lower_limit>
            <ci_upper_limit>-23.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-30.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.74</ci_lower_limit>
            <ci_upper_limit>-24.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.66</ci_lower_limit>
            <ci_upper_limit>-38.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.01</ci_lower_limit>
            <ci_upper_limit>-35.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-30.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.68</ci_lower_limit>
            <ci_upper_limit>-23.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.79</ci_lower_limit>
            <ci_upper_limit>-18.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.77</ci_lower_limit>
            <ci_upper_limit>-37.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.04</ci_lower_limit>
            <ci_upper_limit>-39.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.65</ci_lower_limit>
            <ci_upper_limit>-35.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.72</ci_lower_limit>
            <ci_upper_limit>-28.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.83</ci_lower_limit>
            <ci_upper_limit>-42.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.67</ci_lower_limit>
            <ci_upper_limit>-38.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41" spread="2.03"/>
                    <measurement group_id="O2" value="0.78" spread="2.29"/>
                    <measurement group_id="O3" value="-15.77" spread="2.14"/>
                    <measurement group_id="O4" value="-11.47" spread="2.29"/>
                    <measurement group_id="O5" value="-53.56" spread="1.48"/>
                    <measurement group_id="O6" value="-53.33" spread="1.58"/>
                    <measurement group_id="O7" value="4.48" spread="3.04"/>
                    <measurement group_id="O8" value="5.79" spread="2.79"/>
                    <measurement group_id="O9" value="-15.17" spread="2.99"/>
                    <measurement group_id="O10" value="-12.91" spread="2.80"/>
                    <measurement group_id="O11" value="-52.43" spread="2.14"/>
                    <measurement group_id="O12" value="-56.20" spread="1.98"/>
                    <measurement group_id="O13" value="2.82" spread="2.26"/>
                    <measurement group_id="O14" value="2.58" spread="2.05"/>
                    <measurement group_id="O15" value="-52.46" spread="1.67"/>
                    <measurement group_id="O16" value="-56.66" spread="1.43"/>
                    <measurement group_id="O17" value="2.17" spread="2.56"/>
                    <measurement group_id="O18" value="2.60" spread="2.97"/>
                    <measurement group_id="O19" value="-48.47" spread="1.83"/>
                    <measurement group_id="O20" value="-54.17" spread="2.04"/>
                    <measurement group_id="O21" value="-1.00" spread="3.12"/>
                    <measurement group_id="O22" value="-1.42" spread="4.22"/>
                    <measurement group_id="O23" value="-58.76" spread="2.73"/>
                    <measurement group_id="O24" value="-57.47" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.91</ci_lower_limit>
            <ci_upper_limit>-55.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.57</ci_lower_limit>
            <ci_upper_limit>-48.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.80</ci_lower_limit>
            <ci_upper_limit>-32.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.34</ci_lower_limit>
            <ci_upper_limit>-36.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.22</ci_lower_limit>
            <ci_upper_limit>-49.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.68</ci_lower_limit>
            <ci_upper_limit>-55.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.48</ci_lower_limit>
            <ci_upper_limit>-30.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.07</ci_lower_limit>
            <ci_upper_limit>-36.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.79</ci_lower_limit>
            <ci_upper_limit>-49.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.16</ci_lower_limit>
            <ci_upper_limit>-54.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.82</ci_lower_limit>
            <ci_upper_limit>-44.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.91</ci_lower_limit>
            <ci_upper_limit>-49.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.51</ci_lower_limit>
            <ci_upper_limit>-52.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.85</ci_lower_limit>
            <ci_upper_limit>-50.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="2.20"/>
                    <measurement group_id="O2" value="-1.21" spread="2.41"/>
                    <measurement group_id="O3" value="-14.51" spread="2.31"/>
                    <measurement group_id="O4" value="-12.33" spread="2.41"/>
                    <measurement group_id="O5" value="-54.17" spread="1.59"/>
                    <measurement group_id="O6" value="-49.65" spread="1.69"/>
                    <measurement group_id="O7" value="4.19" spread="3.25"/>
                    <measurement group_id="O8" value="6.50" spread="3.18"/>
                    <measurement group_id="O9" value="-13.69" spread="3.17"/>
                    <measurement group_id="O10" value="-12.19" spread="3.17"/>
                    <measurement group_id="O11" value="-53.59" spread="2.26"/>
                    <measurement group_id="O12" value="-50.76" spread="2.26"/>
                    <measurement group_id="O13" value="1.44" spread="2.30"/>
                    <measurement group_id="O14" value="4.00" spread="2.27"/>
                    <measurement group_id="O15" value="-52.97" spread="1.69"/>
                    <measurement group_id="O16" value="-52.13" spread="1.60"/>
                    <measurement group_id="O17" value="1.64" spread="2.75"/>
                    <measurement group_id="O18" value="3.16" spread="3.51"/>
                    <measurement group_id="O19" value="-47.53" spread="1.96"/>
                    <measurement group_id="O20" value="-45.65" spread="2.39"/>
                    <measurement group_id="O21" value="-1.80" spread="3.21"/>
                    <measurement group_id="O22" value="-0.52" spread="4.29"/>
                    <measurement group_id="O23" value="-59.53" spread="2.77"/>
                    <measurement group_id="O24" value="-52.56" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.65</ci_lower_limit>
            <ci_upper_limit>-54.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.23</ci_lower_limit>
            <ci_upper_limit>-42.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.09</ci_lower_limit>
            <ci_upper_limit>-34.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.12</ci_lower_limit>
            <ci_upper_limit>-31.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.55</ci_lower_limit>
            <ci_upper_limit>-49.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.91</ci_lower_limit>
            <ci_upper_limit>-49.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.53</ci_lower_limit>
            <ci_upper_limit>-32.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.26</ci_lower_limit>
            <ci_upper_limit>-30.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.99</ci_lower_limit>
            <ci_upper_limit>-48.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.58</ci_lower_limit>
            <ci_upper_limit>-50.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.80</ci_lower_limit>
            <ci_upper_limit>-42.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-48.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.21</ci_lower_limit>
            <ci_upper_limit>-40.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.82</ci_lower_limit>
            <ci_upper_limit>-52.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.10</ci_lower_limit>
            <ci_upper_limit>-45.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="1.9" upper_limit="15.4"/>
                    <measurement group_id="O2" value="5.6" lower_limit="1.9" upper_limit="15.1"/>
                    <measurement group_id="O3" value="20.0" lower_limit="11.2" upper_limit="33.0"/>
                    <measurement group_id="O4" value="16.7" lower_limit="9.0" upper_limit="28.7"/>
                    <measurement group_id="O5" value="88.1" lower_limit="80.7" upper_limit="92.9"/>
                    <measurement group_id="O6" value="85.8" lower_limit="78.0" upper_limit="91.2"/>
                    <measurement group_id="O7" value="13.7" lower_limit="6.8" upper_limit="25.7"/>
                    <measurement group_id="O8" value="9.3" lower_limit="4.0" upper_limit="19.9"/>
                    <measurement group_id="O9" value="50.9" lower_limit="38.1" upper_limit="63.6"/>
                    <measurement group_id="O10" value="62.3" lower_limit="48.8" upper_limit="74.1"/>
                    <measurement group_id="O11" value="94.4" lower_limit="88.4" upper_limit="97.4"/>
                    <measurement group_id="O12" value="92.5" lower_limit="85.9" upper_limit="96.2"/>
                    <measurement group_id="O13" value="7.0" lower_limit="2.8" upper_limit="16.7"/>
                    <measurement group_id="O14" value="5.3" lower_limit="1.8" upper_limit="14.4"/>
                    <measurement group_id="O15" value="88.7" lower_limit="81.2" upper_limit="93.4"/>
                    <measurement group_id="O16" value="89.9" lower_limit="82.8" upper_limit="94.3"/>
                    <measurement group_id="O17" value="38.9" lower_limit="27.0" upper_limit="52.2"/>
                    <measurement group_id="O18" value="28.8" lower_limit="18.3" upper_limit="42.3"/>
                    <measurement group_id="O19" value="93.5" lower_limit="87.1" upper_limit="96.8"/>
                    <measurement group_id="O20" value="94.5" lower_limit="88.6" upper_limit="97.5"/>
                    <measurement group_id="O21" value="1.9" lower_limit="0.3" upper_limit="9.8"/>
                    <measurement group_id="O22" value="3.9" lower_limit="1.1" upper_limit="13.2"/>
                    <measurement group_id="O23" value="93.6" lower_limit="87.3" upper_limit="96.9"/>
                    <measurement group_id="O24" value="88.5" lower_limit="81.3" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>82.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.2</ci_lower_limit>
            <ci_upper_limit>88.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>80.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.9</ci_lower_limit>
            <ci_upper_limit>86.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>68.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.1</ci_lower_limit>
            <ci_upper_limit>78.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>69.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.8</ci_lower_limit>
            <ci_upper_limit>78.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>80.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.3</ci_lower_limit>
            <ci_upper_limit>88.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>83.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.7</ci_lower_limit>
            <ci_upper_limit>89.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>43.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.5</ci_lower_limit>
            <ci_upper_limit>56.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>30.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.7</ci_lower_limit>
            <ci_upper_limit>44.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>81.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.5</ci_lower_limit>
            <ci_upper_limit>88.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>84.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.1</ci_lower_limit>
            <ci_upper_limit>90.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>54.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.8</ci_lower_limit>
            <ci_upper_limit>66.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>65.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51.0</ci_lower_limit>
            <ci_upper_limit>76.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>91.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.6</ci_lower_limit>
            <ci_upper_limit>95.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>84.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.8</ci_lower_limit>
            <ci_upper_limit>90.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved LDL-C &lt; 70 mg/dL at Week 12</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.3" upper_limit="10.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="2.0" upper_limit="15.9"/>
                    <measurement group_id="O3" value="22.4" lower_limit="13.0" upper_limit="35.9"/>
                    <measurement group_id="O4" value="19.2" lower_limit="10.8" upper_limit="31.9"/>
                    <measurement group_id="O5" value="85.4" lower_limit="77.4" upper_limit="91.0"/>
                    <measurement group_id="O6" value="84.2" lower_limit="75.8" upper_limit="90.0"/>
                    <measurement group_id="O7" value="13.0" lower_limit="6.1" upper_limit="25.7"/>
                    <measurement group_id="O8" value="9.8" lower_limit="4.3" upper_limit="21.0"/>
                    <measurement group_id="O9" value="52.0" lower_limit="38.5" upper_limit="65.2"/>
                    <measurement group_id="O10" value="55.8" lower_limit="42.3" upper_limit="68.4"/>
                    <measurement group_id="O11" value="93.1" lower_limit="86.5" upper_limit="96.6"/>
                    <measurement group_id="O12" value="91.0" lower_limit="83.8" upper_limit="95.2"/>
                    <measurement group_id="O13" value="7.7" lower_limit="3.0" upper_limit="18.2"/>
                    <measurement group_id="O14" value="5.5" lower_limit="1.9" upper_limit="14.9"/>
                    <measurement group_id="O15" value="85.0" lower_limit="76.7" upper_limit="90.7"/>
                    <measurement group_id="O16" value="86.5" lower_limit="78.7" upper_limit="91.8"/>
                    <measurement group_id="O17" value="39.6" lower_limit="27.6" upper_limit="53.1"/>
                    <measurement group_id="O18" value="28.0" lower_limit="17.5" upper_limit="41.7"/>
                    <measurement group_id="O19" value="92.3" lower_limit="85.6" upper_limit="96.1"/>
                    <measurement group_id="O20" value="92.3" lower_limit="85.6" upper_limit="96.1"/>
                    <measurement group_id="O21" value="1.9" lower_limit="0.3" upper_limit="10.1"/>
                    <measurement group_id="O22" value="6.4" lower_limit="2.2" upper_limit="17.2"/>
                    <measurement group_id="O23" value="94.4" lower_limit="88.4" upper_limit="97.4"/>
                    <measurement group_id="O24" value="84.8" lower_limit="76.7" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>83.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.9</ci_lower_limit>
            <ci_upper_limit>89.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>78.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.2</ci_lower_limit>
            <ci_upper_limit>85.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>63.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.3</ci_lower_limit>
            <ci_upper_limit>73.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>64.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.8</ci_lower_limit>
            <ci_upper_limit>75.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>80.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.8</ci_lower_limit>
            <ci_upper_limit>87.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>81.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.9</ci_lower_limit>
            <ci_upper_limit>88.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>41.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.4</ci_lower_limit>
            <ci_upper_limit>55.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>35.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>49.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>77.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.9</ci_lower_limit>
            <ci_upper_limit>84.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>81.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.8</ci_lower_limit>
            <ci_upper_limit>87.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>52.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.6</ci_lower_limit>
            <ci_upper_limit>65.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>64.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.1</ci_lower_limit>
            <ci_upper_limit>75.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>92.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.3</ci_lower_limit>
            <ci_upper_limit>95.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>78.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.9</ci_lower_limit>
            <ci_upper_limit>85.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="2.86"/>
                    <measurement group_id="O2" value="-0.77" spread="3.28"/>
                    <measurement group_id="O3" value="1.44" spread="3.02"/>
                    <measurement group_id="O4" value="6.85" spread="3.29"/>
                    <measurement group_id="O5" value="-26.01" spread="2.08"/>
                    <measurement group_id="O6" value="-22.64" spread="2.27"/>
                    <measurement group_id="O7" value="-3.45" spread="2.99"/>
                    <measurement group_id="O8" value="1.51" spread="3.35"/>
                    <measurement group_id="O9" value="8.05" spread="2.94"/>
                    <measurement group_id="O10" value="9.96" spread="3.40"/>
                    <measurement group_id="O11" value="-23.97" spread="2.10"/>
                    <measurement group_id="O12" value="-27.46" spread="2.39"/>
                    <measurement group_id="O13" value="11.41" spread="3.00"/>
                    <measurement group_id="O14" value="3.65" spread="3.56"/>
                    <measurement group_id="O15" value="-24.26" spread="2.21"/>
                    <measurement group_id="O16" value="-23.16" spread="2.50"/>
                    <measurement group_id="O17" value="8.59" spread="2.98"/>
                    <measurement group_id="O18" value="6.26" spread="3.59"/>
                    <measurement group_id="O19" value="-24.96" spread="2.12"/>
                    <measurement group_id="O20" value="-25.93" spread="2.46"/>
                    <measurement group_id="O21" value="-10.57" spread="4.49"/>
                    <measurement group_id="O22" value="-4.99" spread="5.37"/>
                    <measurement group_id="O23" value="-38.64" spread="3.92"/>
                    <measurement group_id="O24" value="-32.16" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.06</ci_lower_limit>
            <ci_upper_limit>-25.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-21.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.70</ci_lower_limit>
            <ci_upper_limit>-14.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.53</ci_lower_limit>
            <ci_upper_limit>-20.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.36</ci_lower_limit>
            <ci_upper_limit>-21.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.71</ci_lower_limit>
            <ci_upper_limit>-13.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.01</ci_lower_limit>
            <ci_upper_limit>-20.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.11</ci_lower_limit>
            <ci_upper_limit>-24.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.61</ci_lower_limit>
            <ci_upper_limit>-29.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.94</ci_lower_limit>
            <ci_upper_limit>-28.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-26.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.36</ci_lower_limit>
            <ci_upper_limit>-18.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.74</ci_lower_limit>
            <ci_upper_limit>-26.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.80</ci_lower_limit>
            <ci_upper_limit>-23.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.91</ci_lower_limit>
            <ci_upper_limit>-21.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.59</ci_lower_limit>
            <ci_upper_limit>-19.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread="3.13"/>
                    <measurement group_id="O2" value="-0.43" spread="3.38"/>
                    <measurement group_id="O3" value="3.29" spread="3.28"/>
                    <measurement group_id="O4" value="7.18" spread="3.38"/>
                    <measurement group_id="O5" value="-25.87" spread="2.26"/>
                    <measurement group_id="O6" value="-20.25" spread="2.36"/>
                    <measurement group_id="O7" value="-2.23" spread="3.35"/>
                    <measurement group_id="O8" value="3.41" spread="3.54"/>
                    <measurement group_id="O9" value="8.01" spread="3.26"/>
                    <measurement group_id="O10" value="10.20" spread="3.57"/>
                    <measurement group_id="O11" value="-24.61" spread="2.31"/>
                    <measurement group_id="O12" value="-24.68" spread="2.53"/>
                    <measurement group_id="O13" value="11.40" spread="3.37"/>
                    <measurement group_id="O14" value="4.49" spread="3.68"/>
                    <measurement group_id="O15" value="-25.09" spread="2.47"/>
                    <measurement group_id="O16" value="-20.85" spread="2.59"/>
                    <measurement group_id="O17" value="10.38" spread="3.09"/>
                    <measurement group_id="O18" value="10.21" spread="4.36"/>
                    <measurement group_id="O19" value="-26.11" spread="2.21"/>
                    <measurement group_id="O20" value="-21.97" spread="2.97"/>
                    <measurement group_id="O21" value="-6.81" spread="4.57"/>
                    <measurement group_id="O22" value="-1.06" spread="5.67"/>
                    <measurement group_id="O23" value="-38.06" spread="3.96"/>
                    <measurement group_id="O24" value="-29.23" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.81</ci_lower_limit>
            <ci_upper_limit>-25.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-19.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.92</ci_lower_limit>
            <ci_upper_limit>-11.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.87</ci_lower_limit>
            <ci_upper_limit>-21.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.56</ci_lower_limit>
            <ci_upper_limit>-19.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-22.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.39</ci_lower_limit>
            <ci_upper_limit>-14.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.62</ci_lower_limit>
            <ci_upper_limit>-19.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.46</ci_lower_limit>
            <ci_upper_limit>-24.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.52</ci_lower_limit>
            <ci_upper_limit>-26.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.69</ci_lower_limit>
            <ci_upper_limit>-28.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.19</ci_lower_limit>
            <ci_upper_limit>-16.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.95</ci_lower_limit>
            <ci_upper_limit>-29.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.61</ci_lower_limit>
            <ci_upper_limit>-21.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.40</ci_lower_limit>
            <ci_upper_limit>-24.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.79</ci_lower_limit>
            <ci_upper_limit>-19.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="3.94"/>
                    <measurement group_id="O2" value="9.17" spread="4.41"/>
                    <measurement group_id="O3" value="-3.16" spread="4.10"/>
                    <measurement group_id="O4" value="1.57" spread="4.35"/>
                    <measurement group_id="O5" value="-5.61" spread="2.81"/>
                    <measurement group_id="O6" value="-13.38" spread="3.08"/>
                    <measurement group_id="O7" value="6.16" spread="4.02"/>
                    <measurement group_id="O8" value="8.05" spread="4.35"/>
                    <measurement group_id="O9" value="-8.10" spread="3.92"/>
                    <measurement group_id="O10" value="-4.86" spread="4.39"/>
                    <measurement group_id="O11" value="-9.27" spread="2.80"/>
                    <measurement group_id="O12" value="-6.36" spread="3.11"/>
                    <measurement group_id="O13" value="12.43" spread="4.19"/>
                    <measurement group_id="O14" value="12.26" spread="4.67"/>
                    <measurement group_id="O15" value="-10.28" spread="3.04"/>
                    <measurement group_id="O16" value="-7.26" spread="3.29"/>
                    <measurement group_id="O17" value="8.44" spread="3.76"/>
                    <measurement group_id="O18" value="10.75" spread="3.98"/>
                    <measurement group_id="O19" value="-9.15" spread="2.70"/>
                    <measurement group_id="O20" value="-15.43" spread="2.77"/>
                    <measurement group_id="O21" value="9.29" spread="6.97"/>
                    <measurement group_id="O22" value="13.78" spread="7.44"/>
                    <measurement group_id="O23" value="-11.67" spread="5.97"/>
                    <measurement group_id="O24" value="-15.93" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-12.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.63</ci_lower_limit>
            <ci_upper_limit>-2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-22.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.13</ci_lower_limit>
            <ci_upper_limit>-11.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-2.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.09</ci_lower_limit>
            <ci_upper_limit>7.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-14.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.46</ci_lower_limit>
            <ci_upper_limit>-4.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-15.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.06</ci_lower_limit>
            <ci_upper_limit>-5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-14.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.90</ci_lower_limit>
            <ci_upper_limit>-3.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.63</ci_lower_limit>
            <ci_upper_limit>8.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.12</ci_lower_limit>
            <ci_upper_limit>9.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-22.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.90</ci_lower_limit>
            <ci_upper_limit>-12.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-19.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.76</ci_lower_limit>
            <ci_upper_limit>-8.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-17.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.71</ci_lower_limit>
            <ci_upper_limit>-8.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-26.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.76</ci_lower_limit>
            <ci_upper_limit>-16.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.38</ci_lower_limit>
            <ci_upper_limit>-9.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.84</ci_lower_limit>
            <ci_upper_limit>-18.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="5.23"/>
                    <measurement group_id="O2" value="14.35" spread="5.92"/>
                    <measurement group_id="O3" value="-0.43" spread="5.39"/>
                    <measurement group_id="O4" value="4.88" spread="5.84"/>
                    <measurement group_id="O5" value="-3.79" spread="3.72"/>
                    <measurement group_id="O6" value="-13.26" spread="4.17"/>
                    <measurement group_id="O7" value="6.65" spread="4.45"/>
                    <measurement group_id="O8" value="8.22" spread="5.22"/>
                    <measurement group_id="O9" value="-7.40" spread="4.32"/>
                    <measurement group_id="O10" value="-3.11" spread="5.23"/>
                    <measurement group_id="O11" value="-10.07" spread="3.05"/>
                    <measurement group_id="O12" value="-1.10" spread="3.74"/>
                    <measurement group_id="O13" value="13.57" spread="5.76"/>
                    <measurement group_id="O14" value="12.96" spread="5.32"/>
                    <measurement group_id="O15" value="-4.46" spread="4.16"/>
                    <measurement group_id="O16" value="-6.88" spread="3.80"/>
                    <measurement group_id="O17" value="10.97" spread="4.66"/>
                    <measurement group_id="O18" value="10.00" spread="4.38"/>
                    <measurement group_id="O19" value="-5.58" spread="3.34"/>
                    <measurement group_id="O20" value="-10.51" spread="3.04"/>
                    <measurement group_id="O21" value="8.07" spread="6.88"/>
                    <measurement group_id="O22" value="16.72" spread="7.88"/>
                    <measurement group_id="O23" value="-13.71" spread="5.91"/>
                    <measurement group_id="O24" value="-14.65" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-12.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.69</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.86</ci_lower_limit>
            <ci_upper_limit>-13.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-3.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.16</ci_lower_limit>
            <ci_upper_limit>9.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.28</ci_lower_limit>
            <ci_upper_limit>-3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.34</ci_lower_limit>
            <ci_upper_limit>-6.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-9.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.92</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-2.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.05</ci_lower_limit>
            <ci_upper_limit>7.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.66</ci_lower_limit>
            <ci_upper_limit>14.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.03</ci_lower_limit>
            <ci_upper_limit>-4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-19.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.71</ci_lower_limit>
            <ci_upper_limit>-6.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.84</ci_lower_limit>
            <ci_upper_limit>-5.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.04</ci_lower_limit>
            <ci_upper_limit>-9.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-21.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.88</ci_lower_limit>
            <ci_upper_limit>-10.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.10</ci_lower_limit>
            <ci_upper_limit>-18.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51" spread="3.56"/>
                    <measurement group_id="O2" value="9.53" spread="4.45"/>
                    <measurement group_id="O3" value="-5.35" spread="3.74"/>
                    <measurement group_id="O4" value="1.77" spread="4.41"/>
                    <measurement group_id="O5" value="-6.85" spread="2.56"/>
                    <measurement group_id="O6" value="-11.77" spread="3.11"/>
                    <measurement group_id="O7" value="6.24" spread="4.03"/>
                    <measurement group_id="O8" value="8.31" spread="4.26"/>
                    <measurement group_id="O9" value="-8.52" spread="3.93"/>
                    <measurement group_id="O10" value="-6.13" spread="4.31"/>
                    <measurement group_id="O11" value="-8.96" spread="2.82"/>
                    <measurement group_id="O12" value="-6.38" spread="3.05"/>
                    <measurement group_id="O13" value="12.86" spread="3.95"/>
                    <measurement group_id="O14" value="12.54" spread="4.58"/>
                    <measurement group_id="O15" value="-12.22" spread="2.86"/>
                    <measurement group_id="O16" value="-7.25" spread="3.23"/>
                    <measurement group_id="O17" value="7.06" spread="3.76"/>
                    <measurement group_id="O18" value="8.13" spread="3.72"/>
                    <measurement group_id="O19" value="-9.09" spread="2.71"/>
                    <measurement group_id="O20" value="-15.05" spread="2.58"/>
                    <measurement group_id="O21" value="8.64" spread="6.01"/>
                    <measurement group_id="O22" value="16.37" spread="7.15"/>
                    <measurement group_id="O23" value="-14.57" spread="5.17"/>
                    <measurement group_id="O24" value="-16.50" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-13.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.99</ci_lower_limit>
            <ci_upper_limit>-4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-21.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.98</ci_lower_limit>
            <ci_upper_limit>-10.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.27</ci_lower_limit>
            <ci_upper_limit>7.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-13.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.17</ci_lower_limit>
            <ci_upper_limit>-2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-15.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.88</ci_lower_limit>
            <ci_upper_limit>-5.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-14.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.97</ci_lower_limit>
            <ci_upper_limit>-4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.94</ci_lower_limit>
            <ci_upper_limit>9.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.66</ci_lower_limit>
            <ci_upper_limit>10.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.64</ci_lower_limit>
            <ci_upper_limit>-15.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-19.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.81</ci_lower_limit>
            <ci_upper_limit>-8.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.27</ci_lower_limit>
            <ci_upper_limit>-7.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-23.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.11</ci_lower_limit>
            <ci_upper_limit>-14.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-23.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.00</ci_lower_limit>
            <ci_upper_limit>-13.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.60</ci_lower_limit>
            <ci_upper_limit>-22.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.32" spread="4.00"/>
                    <measurement group_id="O2" value="14.74" spread="5.91"/>
                    <measurement group_id="O3" value="-4.61" spread="4.19"/>
                    <measurement group_id="O4" value="3.45" spread="5.89"/>
                    <measurement group_id="O5" value="-6.16" spread="2.88"/>
                    <measurement group_id="O6" value="-11.73" spread="4.16"/>
                    <measurement group_id="O7" value="6.73" spread="4.45"/>
                    <measurement group_id="O8" value="8.54" spread="5.00"/>
                    <measurement group_id="O9" value="-7.92" spread="4.32"/>
                    <measurement group_id="O10" value="-6.00" spread="5.04"/>
                    <measurement group_id="O11" value="-9.69" spread="3.05"/>
                    <measurement group_id="O12" value="-1.06" spread="3.58"/>
                    <measurement group_id="O13" value="13.79" spread="5.05"/>
                    <measurement group_id="O14" value="12.47" spread="5.31"/>
                    <measurement group_id="O15" value="-8.20" spread="3.64"/>
                    <measurement group_id="O16" value="-6.28" spread="3.78"/>
                    <measurement group_id="O17" value="10.09" spread="4.65"/>
                    <measurement group_id="O18" value="8.59" spread="4.37"/>
                    <measurement group_id="O19" value="-6.10" spread="3.33"/>
                    <measurement group_id="O20" value="-9.95" spread="3.03"/>
                    <measurement group_id="O21" value="7.63" spread="6.26"/>
                    <measurement group_id="O22" value="20.97" spread="7.53"/>
                    <measurement group_id="O23" value="-14.83" spread="5.30"/>
                    <measurement group_id="O24" value="-15.86" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-14.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.16</ci_lower_limit>
            <ci_upper_limit>-4.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-26.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.71</ci_lower_limit>
            <ci_upper_limit>-12.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.41</ci_lower_limit>
            <ci_upper_limit>8.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-15.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.40</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.05</ci_lower_limit>
            <ci_upper_limit>-5.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-9.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.68</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.16</ci_lower_limit>
            <ci_upper_limit>8.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>4.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.25</ci_lower_limit>
            <ci_upper_limit>17.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-21.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.24</ci_lower_limit>
            <ci_upper_limit>-9.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.60</ci_lower_limit>
            <ci_upper_limit>-5.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.46</ci_lower_limit>
            <ci_upper_limit>-4.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.04</ci_lower_limit>
            <ci_upper_limit>-8.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-22.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.09</ci_lower_limit>
            <ci_upper_limit>-11.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.96</ci_lower_limit>
            <ci_upper_limit>-24.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="1.50"/>
                    <measurement group_id="O2" value="-0.45" spread="1.94"/>
                    <measurement group_id="O3" value="-1.13" spread="1.56"/>
                    <measurement group_id="O4" value="-0.92" spread="1.92"/>
                    <measurement group_id="O5" value="5.54" spread="1.07"/>
                    <measurement group_id="O6" value="7.66" spread="1.37"/>
                    <measurement group_id="O7" value="4.48" spread="1.73"/>
                    <measurement group_id="O8" value="-1.37" spread="1.85"/>
                    <measurement group_id="O9" value="0.86" spread="1.68"/>
                    <measurement group_id="O10" value="-0.59" spread="1.86"/>
                    <measurement group_id="O11" value="8.44" spread="1.20"/>
                    <measurement group_id="O12" value="7.76" spread="1.31"/>
                    <measurement group_id="O13" value="0.87" spread="1.52"/>
                    <measurement group_id="O14" value="-0.94" spread="2.55"/>
                    <measurement group_id="O15" value="6.23" spread="1.10"/>
                    <measurement group_id="O16" value="7.72" spread="1.80"/>
                    <measurement group_id="O17" value="-0.60" spread="1.56"/>
                    <measurement group_id="O18" value="-0.40" spread="1.81"/>
                    <measurement group_id="O19" value="4.86" spread="1.12"/>
                    <measurement group_id="O20" value="6.35" spread="1.26"/>
                    <measurement group_id="O21" value="0.13" spread="2.75"/>
                    <measurement group_id="O22" value="-2.14" spread="2.72"/>
                    <measurement group_id="O23" value="10.35" spread="2.26"/>
                    <measurement group_id="O24" value="6.71" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.91</ci_lower_limit>
            <ci_upper_limit>10.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.43</ci_lower_limit>
            <ci_upper_limit>12.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.00</ci_lower_limit>
            <ci_upper_limit>10.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.93</ci_lower_limit>
            <ci_upper_limit>13.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>3.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>8.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>9.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.68</ci_lower_limit>
            <ci_upper_limit>13.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.51</ci_lower_limit>
            <ci_upper_limit>11.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.86</ci_lower_limit>
            <ci_upper_limit>12.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>9.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>14.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>9.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.40</ci_lower_limit>
            <ci_upper_limit>11.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>10.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.13</ci_lower_limit>
            <ci_upper_limit>15.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.73</ci_lower_limit>
            <ci_upper_limit>12.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>A10 PBO Q2W</title>
            <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>A10 PBO QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>A10 EZE (Q2W)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>A10 EZE (QM)</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>A10 EvoMab Q2W</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>A10 EvoMab QM</title>
            <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>A80 PBO Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>A80 PBO QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>A80 EZE (Q2W)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O10">
            <title>A80 EZE (QM)</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>A80 EvoMab Q2W</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>A80 EvoMab QM</title>
            <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>R5 PBO Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O14">
            <title>R5 PBO QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O15">
            <title>R5 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O16">
            <title>R5 EvoMab QM</title>
            <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O17">
            <title>R40 PBO Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O18">
            <title>R40 PBO QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O19">
            <title>R40 EvoMab Q2W</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O20">
            <title>R40 EvoMab QM</title>
            <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O21">
            <title>S40 PBO Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O22">
            <title>S40 PBO QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
          <group group_id="O23">
            <title>S40 EvoMab Q2W</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
          </group>
          <group group_id="O24">
            <title>S40 EvoMab QM</title>
            <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="110"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="56"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="109"/>
                <count group_id="O12" value="110"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="57"/>
                <count group_id="O15" value="113"/>
                <count group_id="O16" value="115"/>
                <count group_id="O17" value="56"/>
                <count group_id="O18" value="55"/>
                <count group_id="O19" value="111"/>
                <count group_id="O20" value="112"/>
                <count group_id="O21" value="56"/>
                <count group_id="O22" value="55"/>
                <count group_id="O23" value="112"/>
                <count group_id="O24" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.72"/>
                    <measurement group_id="O2" value="0.01" spread="2.02"/>
                    <measurement group_id="O3" value="-1.76" spread="1.78"/>
                    <measurement group_id="O4" value="-0.40" spread="1.99"/>
                    <measurement group_id="O5" value="7.04" spread="1.23"/>
                    <measurement group_id="O6" value="7.88" spread="1.42"/>
                    <measurement group_id="O7" value="5.02" spread="1.88"/>
                    <measurement group_id="O8" value="0.30" spread="2.01"/>
                    <measurement group_id="O9" value="0.62" spread="1.83"/>
                    <measurement group_id="O10" value="0.21" spread="2.01"/>
                    <measurement group_id="O11" value="9.09" spread="1.29"/>
                    <measurement group_id="O12" value="7.36" spread="1.43"/>
                    <measurement group_id="O13" value="2.87" spread="1.87"/>
                    <measurement group_id="O14" value="-0.16" spread="2.64"/>
                    <measurement group_id="O15" value="6.07" spread="1.35"/>
                    <measurement group_id="O16" value="7.18" spread="1.87"/>
                    <measurement group_id="O17" value="-0.39" spread="1.86"/>
                    <measurement group_id="O18" value="0.73" spread="1.98"/>
                    <measurement group_id="O19" value="4.65" spread="1.34"/>
                    <measurement group_id="O20" value="5.57" spread="1.37"/>
                    <measurement group_id="O21" value="1.14" spread="2.96"/>
                    <measurement group_id="O22" value="-2.65" spread="2.87"/>
                    <measurement group_id="O23" value="10.92" spread="2.38"/>
                    <measurement group_id="O24" value="6.41" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.66</ci_lower_limit>
            <ci_upper_limit>10.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.01</ci_lower_limit>
            <ci_upper_limit>12.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.58</ci_lower_limit>
            <ci_upper_limit>13.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.46</ci_lower_limit>
            <ci_upper_limit>13.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>4.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>8.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>11.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.07</ci_lower_limit>
            <ci_upper_limit>12.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>11.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>3.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>7.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>13.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O19</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>9.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O18</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>4.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>9.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O21</group_id>
              <group_id>O23</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>9.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.05</ci_lower_limit>
            <ci_upper_limit>15.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O22</group_id>
              <group_id>O24</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>9.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.40</ci_lower_limit>
            <ci_upper_limit>13.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of blinded investigational product until the end of the study (up to 14 weeks).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>A10 PBO Q2W</title>
          <description>Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>A10 PBO QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>A10 EZE (Q2W)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>A10 EZE (QM)</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>A10 EvoMab Q2W</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>A10 EvoMab QM</title>
          <description>Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>A80 PBO Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>A80 PBO QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>A80 EZE (Q2W)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E10">
          <title>A80 EZE (QM)</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E11">
          <title>A80 EvoMab Q2W</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E12">
          <title>A80 EvoMab QM</title>
          <description>Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E13">
          <title>R5 PBO Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E14">
          <title>R5 PBO QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="E15">
          <title>R5 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E16">
          <title>R5 EvoMab QM</title>
          <description>Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="E17">
          <title>R40 PBO Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E18">
          <title>R40 PBO QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="E19">
          <title>R40 EvoMab Q2W</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E20">
          <title>R40 EvoMab QM</title>
          <description>Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="E21">
          <title>S40 PBO Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E22">
          <title>S40 PBO QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
        <group group_id="E23">
          <title>S40 EvoMab Q2W</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.</description>
        </group>
        <group group_id="E24">
          <title>S40 EvoMab QM</title>
          <description>Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Herpes simplex meningoencephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pleomorphic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="11" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="2" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E24" subjects_affected="5" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

